Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.
about
Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathyMicroRNA-regulated viral vectors for gene therapymiRNA therapeutics in cardiovascular diseases: promises and problemsOptogenetics-enabled assessment of viral gene and cell therapy for restoration of cardiac excitability.Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failureMybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in miceEarly heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN deliveryHeart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodelingSmall and large animal models in cardiac contraction research: advantages and disadvantagesMRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2.Gene delivery to the spinal cord using MRI-guided focused ultrasoundA single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction.Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications.Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skippingGene transfer in skeletal and cardiac muscle using recombinant adeno-associated virusAngiopoietin 2 mediates microvascular and hemodynamic alterations in sepsisOxidative stress decreases microtubule growth and stability in ventricular myocytesSystemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic miceMyostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model.Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Macaca mulatta) brainsTransduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblastsMitochondria-localized caveolin in adaptation to cellular stress and injury.Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.SERCA2a gene therapy can improve symptomatic heart failure in δ-sarcoglycan-deficient animals.AAV serotype influences gene transfer in corneal stroma in vivo.RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disordersAdeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle.Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathyMammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications.The AAV9 receptor and its modification to improve in vivo lung gene transfer in miceAn AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse modelsAAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.Development of viral vectors for use in cardiovascular gene therapy.The evolution of heart gene delivery vectorsDecreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN deliveryPartial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy.MicroRNA therapeutics in cardiovascular medicine.
P2860
Q24562178-0924E2B2-034D-47F5-987E-432D0FF2AB96Q26745822-22524EA8-F473-4CF2-BAA8-0FCB241F0FD4Q26801614-F841C1A6-D4D5-4D71-8252-F0B85A41B4E5Q27304840-89DDEE86-2615-43D5-A072-1C5A42D0E39CQ27318604-75559001-D8B7-4F56-A1F2-70C9AA852769Q28253008-BF04F65A-6B57-4D7D-8081-C069E85EC703Q28288188-DFDC8C5F-E0FF-424B-AE5A-2367E0CFCA9AQ28482901-487BC8E9-B614-43E5-9090-A094BF1CF195Q28658055-7AABB30A-33E7-42DD-8BE7-BB96EF4CCCBFQ30317274-552A3050-D29A-47A8-A286-06E01EC2BD15Q30394722-B2770BDC-9DB7-403F-9F2D-79DA622BEECFQ30413864-DA2316B3-9B90-44E1-B599-0C62A55DE95CQ30427066-FECBF8EA-6A53-4E3C-AEFA-7ECFB1DD76D4Q30431585-8AF49651-8DA3-4BEC-A132-9E6DEE9949AEQ30514014-6402AC47-0CAC-4F96-B726-502A0383A4B7Q30539495-36D80D32-2AB7-4029-B561-A9DA300652F2Q30541878-1E6D3ABA-6C9C-4F49-AD6D-6AFB1DECCA3AQ30770438-2637C7CD-5F2A-4644-B25A-F0B044C98B42Q33531816-1AF873DF-10F6-4271-A4F4-3FB89B64D665Q33564220-4A1B12F0-C79E-4EA6-9C3F-19C552F904FBQ33577391-C623575B-FEE5-459B-8145-9C93D2956033Q33624247-8E826FD3-9949-45B9-80E9-6EEA62E877D3Q33729738-655EEB4C-FC6A-4F50-B518-43613F948E0EQ33833473-8C28B74C-572A-4090-8BE0-501E2C62C529Q33902499-118A8848-D931-4617-8A63-292E2AB7B017Q34063645-13E651A0-FBB5-4608-9775-99ADCD3055FFQ34079531-0A2E7FD9-82AD-4EAB-8EE8-A8CFFF5B7FBFQ34166253-0C9553AA-DBF4-49FB-A565-EBC90A96AC6EQ34205620-32125938-AC82-48D5-80E0-6F3FAA1F9DC8Q34211478-A72CE591-375B-476A-8DF0-6469DF7EB184Q34221578-B0C1796C-BF1A-46EC-A764-F596461663C7Q34497055-37ED8D31-C27A-467D-B0C0-A67E8B6156C1Q35015807-1A7FEDF6-915C-4ED4-B2F9-F593E1E055FAQ35184184-F31263C9-E283-477B-8A38-B8AFEF854FD1Q35238264-83DC20F8-1295-48CE-8EFD-B2656F250154Q35260617-7D189F50-E948-49B6-9072-EA6224B193ADQ35799722-EC72C25F-F701-403B-A5D7-1DA23279E059Q35823950-2903C04F-9459-41EE-A6CB-269D3BE558D3Q35892582-7D1E6C83-97FD-4D1D-939C-1BB434C66DB6Q36037919-ADD08F21-CA33-4720-9C31-38BA294A6136
P2860
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@ast
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@en
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@nl
type
label
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@ast
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@en
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@nl
prefLabel
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@ast
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@en
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@nl
P2093
P2860
P356
P1433
P1476
Adeno-associated virus (AAV) s ...... and AAV8 in the mouse and rat.
@en
P2093
Guangping Gao
H Lee Sweeney
James M Wilson
Julio Sanmiguel
Kevin Morine
Lawrence T Bish
Meg M Sleeper
P2860
P304
P356
10.1089/HUM.2008.123
P577
2008-12-01T00:00:00Z